Drug intelligence / Profile preview

VIR201

Development stage: Phase 2
Lead developer: Virax Holdings
Modality: Prophylactic Vaccines → Vaccines & Immunotherapeutics, DNA Vaccines → Plasmid DNA → DNA Therapeutics → Nucleic Acid Therapeutics
Administration: Intramuscular

Overview

VIR201 is an experimental DNA vaccine that utilizes Co-X-Gene technology, in which HIV and human genetic material are grafted onto a harmless fowlpox virus. The approach is designed to stimulate an immune response against HIV by introducing genetic material encoding HIV antigens into the body via a viral vector. This vaccine candidate represents a gene-based immunization strategy for the prevention or treatment of HIV infection[1].

Other names: rFPV expressing HIV gag-pol antigensfowlpox virus expressing HIV gag-pol antigens

Targets

gp41 (Human immunodeficiency virus type 1 glycoprotein 41)

Beyond the preview

Go deeper on VIR201.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on VIR201.

Explore the full profile